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Background: Cancer-related cognitive impairment (CRCI) is a prevalent source of comprised quality of life in
cancer survivors. This study evaluated the efficacy of Emotional Freedom Techniques (EFT) on self-reported
CRCI (sr-CRCI).
Methods: In this prospective multicentre randomised wait-list controlled study (ClinicalTrials.gov Identifier:
NCT02771028), eligible cancer survivors had completed curative treatment, were 18 years or older and
screened positive for sr-CRCI with  43 on the Cognitive Failures Questionnaire (CFQ). Participants were
randomised to the immediate treatment group (ITG) or wait-list control (WLC) group, based on age (< or 
65 years), gender, treatment (chemotherapy or not), and centre. The ITG started to apply EFT after inclusion
and performed this for 16 weeks. TheWLC group could only start the application of EFT after 8 weeks of wait-
ing. Evaluations took place at baseline (T0), 8 weeks (T1) and 16 weeks (T2). The primary outcome was the
proportion of patients with sr-CRCI according to the CFQ score.
Findings: Between October 2016 and March 2020, 121 patients were recruited with CFQ  43 indicating sr-
CRCI. At T1, the number of patients scoring positive on the CFQ was significantly reduced in the ITG compared
to the WLC group (40.8% vs. 87.3% respectively; p<0.01). For the WLC group, a reduction in CFQ scores was
observed at T2, comparable to the effect of the ITG at T1. Linear mixed model analyses indicated a statistically
significant reduction in the CFQ score, distress, depressive symptoms, fatigue and also an improvement in
quality of life.
Interpretation: This study provides evidence for the application of EFT for sr-CRCI in cancer survivors and sug-
gests that EFT may be useful for other symptoms in cancer survivors.
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Advances in cancer treatments have significantly increased the
number of cancer survivors with an estimated number of 16.9 million
in the United States (2019) [1]. Despite this record number, someadverse effects of cancer therapies remain present after treatment.
Cancer-related cognitive impairment (CRCI) refers to changes or
impairments in cognitive function associated with a cancer diagnosis
and/or its treatment. This important clinical problem may persist for
months or years after the cancer treatment has ended [2].
These cognitive problems have been defined with terms as che-
mobrain and chemofog. Although widely accepted, the term chemo-
brain is somewhat unfavourable as longitudinal trials have
Research in context
Evidence before this study
Cancer-related cognitive impairment (CRCI) refers to changes
or impairments in cognitive function associated with a cancer
diagnosis and/or its treatment. There is a growing recognition
of the multifactorial, complex nature of CRCI which has led to
research on its aetiology and underlying mechanisms. Distress
has been identified as one of the factors causing subjective or
self-reported CRCI (sr-CRCI). An approach that has received
increasing attention over the past years to deal with several
psychological symptoms such as distress is emotional freedom
techniques (EFT). Clinical EFT is an evidence-based method that
combines elements of cognitive and somatic therapies with
acupressure. This manual stimulation of acupuncture points is
performed while using a spoken affirmation to target a psycho-
logical issue. Before undertaking this study, a literature search
was done in PubMed. An independent EFT practitioner and clin-
ical expert was consulted for the trial development. This
approach has been validated in more than 100 clinical trials
that have shown that EFT is an efficacious and safe self-help
tool to improve both physiological and psychological symptoms
in non-cancer patients.
Added value of this study
The present study aimed to identify EFT as an effective treat-
ment to deal with sr-CRCI by acknowledging it as an effective
self-help stress-reduction technique for cancer survivors who
suffer from sr-CRCI. This is the first study to acknowledge EFT
as an active treatment for sr-CRCI and highlights the potential
of EFT to improve quality of life, distress levels, depressive
symptoms, and fatigue in cancer survivors.
Implication of all the available evidence
As a safe and reliable self-help method, EFT demonstrates clini-
cal utility as a low-cost non-drug treatment for sr-CRCI in can-
cer survivors, easy to implement in clinical practice.
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prior to chemotherapy [36]. Recent investigations established that
other treatments such as targeted therapies can also induce cognitive
deficits [7,8]. CRCI is one of the most feared long-term adverse effects
of a cancer treatment and has been associated with comprised
health-related quality of life (HRQoL) and impaired social and occu-
pational functioning [9]. Reducing those long-term consequences
after cancer treatment, such as cognitive impairment, was recently
described as one of the research priorities by the ASCO [2].
There is a growing recognition of the multifactorial, complex
nature of CRCI which has led to research on its aetiology and underly-
ing mechanisms. Research has shown that neuropsychological disor-
ders in cancer patients can evolve out of psychosocial risk factors
such as distress [10,11]. Distress is defined as an unpleasant experi-
ence of a mental, physical, social, or spiritual nature that may inter-
fere with the ability to cope with cancer [12]. Research by our group
reported that higher levels of distress are associated with subjective
or self-reported CRCI (sr-CRCI) [6,9,13]. Furthermore, distress may
lead to compromised HRQoL if lEFT untreated [12,13]. Overall, anxi-
ety, depression, and fatigue are frequent in cancer patients and have
been associated with CRCI as well [11,1422].
Over the past few years, psychosocial interventions, such as cogni-
tive behaviour therapy (CBT) and mindfulness, are encouraged tohelp patients cope with emotional stress, anxiety and depression
during and after cancer [16,2325]. Long-term trends in the use of
these complementary and alternative medical therapies have led to
the development of novel approaches for treating psychological
symptoms. An approach that has received increasing attention is
emotional freedom techniques (EFT). EFT is a mental or emotional
version of acupressure that can be self-applied for a wide range of
emotional, health, and performance issues [26].
EFT utilizes established techniques including cognitive restructur-
ing, exposure, and systematic desensitization, but it adds the novel
component of stimulating acupuncture points (acupoints) whilst dis-
turbing memories or triggers are mentally activated [27]. The process
involves a ‘Setup Statement’ that consists of a reference to the trau-
matic event or related feelings combined with a self-acceptance
statement and simultaneous acupoint tapping on the side of the
hand. For the remainder of the process, patients gently tap with two
fingers on head and torso points (Fig. 2). During this part the patient
repeats a shortened version of the Setup Statement, usually one or
two words, referred to as the ‘Reminder Phrase’. By tapping the acu-
points, the distress related to the emotional or physical triggering
memory should be reduced.
This approach has been validated in over 100 clinical trials that
have shown that EFT is an efficacious and safe self-help tool that can
be used both on a self-help basis and as a primary evidence-based
treatment to improve both physiological and psychological symp-
toms in a variety of populations [2836]. A first meta-analysis com-
prised 18 randomised controlled trials (RCTs) (n = 921) and found
moderate treatment effect of EFT for psychological conditions [36].
Another meta-analysis included 14 studies (n = 658) and concluded
that EFT therapy is associated with a significant treatment effect for
anxiety (d = 1.23) [30]. Another large treatment effect was detected in
RCTs examining EFT for depression (d = 1.31) [31]. A last meta-analy-
sis showed that a series of 410 EFT sessions creates a large treat-
ment effect for posttraumatic stress disorder (PTSD) (d = 2.96) [28].
Combining brief psychological exposure with the manual stimula-
tion of acupoints is an intervention strategy that integrates estab-
lished clinical principles with methods derived from healing
traditions of Eastern cultures. Several RCTs identified the acupoint
stimulation as an active ingredient of EFT [37].
Moreover, Swingle et al. demonstrated neurophysiological evidence
of the efficacy of EFT using electroencephalogram (EEG) imaging
recording brain waves of car accident victims suffering from PTSD [38].
Another trial concerning PTSD suggested that the stimulation of acu-
points directly sends deactivating signals to the amygdala, resulting in
the rapid attenuation of threat responses to innocuous stimuli [39].
Studies with functional MRI suggest that acupoint tapping is able to
regulate the autonomic nervous system and fear responses [39].
Furthermore, the manual stimulation of acupoints appears to have
a positive effect on cortisol levels(33), but also induces neurochemi-
cal changes which generate a relaxation response which reciprocally
inhibits anxiety and creates a rapid desensitization to traumatic stim-
uli, confirming the mechanism of EFT [40]. The application of EFT also
appears to result in a differential gene expression with an upregula-
tion of immune markers and downregulation of inflammation and
stress markers [4144].
While there are many traditional psychotherapy techniques such
as CBT, EFT may offer significant practical advantages to these well-
known interventions that often include personal guidance and spe-
cific training which generally entail a time-intensive programme.
What makes EFT in particular appealing is that is a low-threshold,
easily accessible tool that is proven to be easily learned, rapidly effec-
tive, safe to use on one's own outside the therapist's office and can be
instructed in groups. Except for a study where EFT was found effec-
tive to reduce the side effects of tamoxifen and aromatase inhibitors
(45) and a trial with spiritual EFT for cancer pain (46), evidence in
cancer patients remains scarce.
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attributed to the technique’s ability to deal with mild to severe dis-
tress [3234,40]. Distress, a component of many emotional and phys-
ical disorders, was also found to be a predictor for sr-CRCI [13]. We
hypothesize that the application of EFT may relieve sr-CRCI in cancer
survivors through a reduction of the level of distress.
2. Methods
2.1. Study design
This prospective multicentre randomised wait-list controlled
study was coordinated by AZ Groeninge Kortrijk (Belgium) and took
place in three Belgian centres: AZ Groeninge Kortrijk, AZ Klina Bras-
schaat, and UZ Brussel (ClinicalTrials.gov Identifier: NCT02771028).
The study was conducted on behalf of the Belgian Society for Medical
Oncology (BSMO) Cancer Survivorship Task Force. Human ethics
approval was obtained by the leading ethics committee of UZ Brussel
(registration number: B143201628822) and the local ethics commit-
tees of AZ Groeninge and AZ Klina. The study period started in Octo-
ber 2016 and patient inclusion was ended in March 2020. The study
was conducted according to good clinical practice guidelines and
reported conform to CONSORT 2010 guidelines. The study protocol is
available (online only).
2.2. Participants
Patients eligible for this study were diagnosed with a solid tumour
or haematologic malignancy and had completed curative cancer
treatment including chemotherapy, radiotherapy, surgery or targeted
therapy. They could continue anti-hormonal treatment. There was no
limitation on time since treatment end. All participants had to be
18 years or older, had an expected life expectancy of at least 5 years,
and suffered from sr-CRCI (CFQ  43). Patients with mental deteriora-
tion, organic brain syndrome, alcohol or drug dependency, or
patients coping with a major psychiatric or neurological disorder that
could potentially invalidate assessment were excluded from partici-
pation. Patients were locally recruited by their treating physicians
and oncopsychologists (MSc). In addition, information brochures and
flyers were distributed at the day clinic and outpatient department at
the three centres. Written informed consent was obtained from all
participants.
2.3. Randomisation
After baseline interview (T0) including the completion of the CFQ,
eligible patients were randomised into one of two groups: an imme-
diate treatment group (ITG) or wait-list control (WLC) group. Imme-
diately after allocation, patients were informed to which group they
were assigned. The ITG started the application of EFT after allocation
and applied this technique for 16 weeks: the first eight weeks they
applied the technique under supervision of the EFT instructor (until
time point T1), while the next eight weeks they were asked to con-
tinue the application of EFT without intervention (‘observation 8
weeks’ until T2). The WLC group could only start the application of
EFT at T1, after eight weeks of waiting. Thereafter, they cross over to
the intervention arm and applied EFT for 8 weeks under supervision
of the EFT instructor, until T2.
Participants were randomly assigned to the ITG or WLC group by
the principle of minimization. Stratification was based on (1) age (<
65 or  65 years); (2) gender (male or female); (3) chemotherapy
(yes or no) and (4) centre of inclusion (AZ Groeninge, AZ Klina and
UZ Brussel). Allocation was performed by the central study coordina-
tor (AZ Groeninge) by computer software developed for this trial.
Subsequently, they were referred to a physician, oncopsychologist or
study trial coordinator (MSc or PhD) qualified and trained to conductthe trial (Association for the Advancement of Meridian Energy Tech-
niques (AAMET) EFT level 1 certificate), present at one of the three
centres (M.L., T.L., C.K., L.T.).
2.4. Procedures
Together with 2 certified EFT practitioners (M.L.,T.L.) and an inde-
pendent EFT practitioner and clinical expert (K.M.), the principal
investigator developed the programme which was based on the stan-
dardized protocol by Craig [45]. The key goals of the EFT intervention
in this study were: to teach a strategy for controlling worry and
excessive distress, to address existential thoughts and worries and to
educate survivors with the self-help stress reduction technique in
order to reduce sr-CRCI.
Following the baseline interview, a first session “how to apply
EFT” took place with the local EFT practitioner. This first session
lasted between 40 and 90 min. A second follow-up session usually
took place one week later and lasted about 10 to 20 min. Patients
were individually guided during study participation and when
desired or needed, sequential sessions were planned in order to stim-
ulate patients and ensure adequate follow-up. Participants were
asked to apply EFT at least once a day and report this in a patient
diary they received upon participation. This diary was not obligatory
to complete, but it could stimulate participants to apply EFT and help
them to monitor their own progress.
Assessments were done at baseline (before randomisation) (time
point 0 (T0)), after eight weeks (T1), and after 16 weeks (T2). Partici-
pants could continue the application of EFT after the period of eight
or 16 weeks. Follow-up evaluation six and 12 months after study par-
ticipation consisted of the EuroQol EQ-5D-3 L and the question if
patients continued the application of EFT.
2.5. Outcomes
The primary outcome was the efficacy of EFT over the course of
eight weeks, assessed by a reduction in sr-CRCI at T1. Presence of sr-
CRCI was defined as presenting with a CFQ score  43. The CFQ rates
subjective cognitive complaints on a Likert scale from 0 to 4 [46].
Total scores range from 0 to 100, with cut-off < 43. Where a normal
score ranges between 21 and 43, significant cognitive complaints
start from a CFQ total score > 42.9 [47]. Other patient-reported out-
come measures (PROMs) evaluated at T0, T1 and T2 included the dis-
tress thermometer (DT) and 38-item problem list (PL)(12, 50); the
Beck Depression Inventory-II (BDI-II))(35, 51) and the Functional
Assessment of Chronic Illness Therapy-Fatigue Subscale (FACIT-
Fatigue)(52). HRQoL was measured using the cancer-specific Euro-
pean Organization for Research and Treatment for Cancer QoL Ques-
tionnaire (EORTC QLQ-C30)(53) and the EuroQol EQ-5D-3L(54). For
the EORTC QLQ-C30, a higher score indicates a better health, except
for the symptom scales where a high score mirrors a high level of
symptomatology. A difference of 10 points on each HRQoL scale or
item is defined as clinically relevant [48]. Demographic details were
self-reported at T0, while clinical details were looked up in the elec-
tronic patient record by the trial coordinator.
2.6. Statistical analyses
Based on a two-sided test for independent proportions and the
assumption to find a difference in proportion of 25% between the ITG
and WLC group at T1, achieving a power of 80% at the 5% significance
level, a sample size of maximum 140 patients and expected dropout
of 15% was considered appropriate. Thus, by including 118 evaluable
patients, the goal was to establish that 25% more patients showed a
reduction in sr-CRCI after EFT intervention in the ITG compared to
the WLC group.
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characteristics. To assess the efficacy of EFT at T1, a x2 (or Fisher
exact) was used and two-sample t-tests were used to compare base-
line characteristics between the ITG and WLC group. Linear mixed-
effects regression models were used to assess whether the improve-
ment in CFQ scores and secondary PROMs were significantly different
over time. Models included the stratification variables (age, gender,
treatment and centre) as fixed effects and time x group as interaction
effect to account for correlation amongst repeated observations per
participant. Estimated marginal means with 95% confidence interval
(CI) were calculated for each time point for both groups. Within-
group differences were obtained by pairwise comparisons, enabling
us to detect differences over time within the ITG and WLC group.
Between-group differences on the other hand, resulted from the esti-
mates of the interaction term time x group with T0 as reference time
point. This outcome represents the difference in slope and measures
the effect of the intervention with EFT.
A 5% significance level was used. All statistical analyses were con-
ducted using IBM SPSS v.26 (SPSS, Inc., Chicago, IL) software.2.7. Role of the funding source
The funders of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report.Fig. 1. CONSORT diagram.3. Results
3.1. Patient demographics
Between October 2016 and March 2020, 143 patients gave
informed consent for cognitive screening with the CFQ (Fig. 1). There
were 22 patients excluded from participation because they did not
have sr-CRCI (CFQ < 43). Finally, 121 patients were eligible for analy-
sis and randomised to the ITG or WLC group. At T1 and T2, respec-
tively 104 and 93 patients completed all questionnaires. The main
reason for drop-out was an emotional unstable situation due to
which cancer survivors were not able to apply EFT adequately, while
a minority (n = 6) dropped out when acceptance was hampered by
the disbelief that the application of EFT could help to overcome seri-
ous sr-CRCI and emotional problems..
Participants had an average age of 52.2 years (range 2878 years).
Women were overrepresented compared to male individuals (93.4%
and 6.6%, respectively). A previous diagnosis of breast cancer was the
main malignant condition (77.7%). Most patients had receivedFig. 2. Head, torso and hand acupressure points involved in the application of EFT (Figure a
forming acupoint tapping on the side of the hand. For the remainder of the process, patient
Phrase’.systemic treatment (86.8%) and/or surgery (87.6%). Baseline patient
characteristics are presented in Table 1 (online only).3.2. The efficacy of EFT for sr-CRCI
At T1, 59.2% of the ITG and 12.7% of the WLC group scored <43 on
the CFQ. These data illustrate that an intervention with EFT signifi-
cantly reduced subjective cognitive complaints with a difference in
proportion of 46.5% between the ITG andWLC group at T1 (p<0.01).
In a linear mixed model for CFQ scores over time, the time x group
interaction effect was found to be significant (p<0.001) as were time
and group separately (p<0.001). Gender was also a significant main
effect (p<0.005), but treatment, centre and age were not.dapted from Church et al. [27]). The process starts with a ‘Setup Statement’ while per-
s gently tap with two fingers on head and torso points while repeating the ‘Reminder
Table 1
Demographic and clinical characteristics (online only).
Characteristics Immediate treatment group Wait-list control group Overall Significance*
Number of Patients 59 62 121 NA
Age (average § SD) 52.0 § 7.7 52.4 § 8.4 52.2 § 8.0 p = 0.78
Age category
< 65 years 56 (94.9%) 58 (93.5%) 114 (94.2%) p = 0.75
 65 years 3 (5.1%) 4 (6.5%) 7 (5.8%)
Gender
Female 55 (93.2%) 58 (93.5%) 113 (93.4%) p = 1.00
Male 4 (6.8%) 4 (6.5%) 8 (6.6%)
Social status
Married/Living together 43 (72.9%) 44 (71.0%) 87 (71.9%) p = 0.71
Single 3 (5.1%) 4 (6.5%) 7 (5.8%)
Divorced 13 (22.0%) 12 (19.4%) 25 (20.7%)
Missing 0 (0%) 1 (1.6%) 1 (0.8%)
Living situation
Home with partner 48 (81.4%) 53 (85.5%) 101 (83.5%) p = 0.75
Home alone 9 (15.3%) 8 (12.9%) 17 (14.0%)
Home with family member 1 (1.7%) 0 (0%) 1 (0.8%)
Missing 1 (1.7%) 1 (1.6%) 2 (1.7%)
Education level
Lower high school 6 (10.2%) 6 (9.7%) 12 (9.9%) p = 0.70
Higher high school 17 (28.8%) 18 (29.0%) 35 (28.9%)
Bachelor degree 22 (37.3%) 30 (48.4%) 52 (43.0%)
Master degree 11 (18.6%) 6 (9.7%) 17 (14.0%)
Other 1 (1.7%) 1 (1.6%) 2 (1.7%)
Missing 2 (3.4%) 1 (1.6%) 3 (2.5%)
Cancer type
Non Hodgkin Lymphoma 2 (3.4%) 5 (8.1%) 7 (5.8%) p = 0.28
Breast 46 (78.0%) 48 (77.4%) 94 (77.7%)
Ovary 4 (6.8%) 2 (3.2%) 6 (5.0%)
Other** 7 (11.9%) 7 (11.3%) 14 (11.6%)
Type of therapy
Surgery 54 (91.5%) 52 (83.9%) 106 (87.6%) p = 0.18
Radiotherapy 46 (78.0%) 45 (72.6%) 91 (75.2%)
Systemic treatment 51 (86.4%) 54 (87.1%) 105 (86.8%)
Hormonal treatment 34 (57.6%) 36 (58.1%) 70 (57.9%)
Other*** 24 (40.7%) 17 (27.4%) 41 (33.9%)
*Baseline characteristics were compared using Exact Pearson Chi-square Tests and two-sample t-tests.
**Other malignancies include Hodgkin Lymphoma, Acute Myeloid Leukaemia, Acute Lymphocytic Leukaemia, Colon, Cervix
uteri, Prostate, Kidney, Melanoma.
***Other types of therapy include targeted therapy and immune therapy.
Abbreviations: SD = standard deviation.
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all time points (Fig. 3). We observed an estimated mean difference of
18.5 points at T1 (95% CI: 21.73, 15.28; p<0.001) which continued
at T2 (3.85; 95% CI:7.32,0.38; p<0.05). For the WLC group, there
was already a significant reduction in sr-CRCI at T1 (4.35; 95% CI:
7.42, 1.28; p<0.01). Further reduction in CFQ score was observed
at T2 (12.86; 95% CI: 16.11, 9.62; p<0.001). Detailed information
on these pairwise comparisons is summarized in Table 2.
The effect of the intervention is measured by the difference in
estimated mean CFQ scores between the ITG and WLC group at T1,
with T0 as reference time point. This between-group difference was
statistically significant at T1 (14.16; 95% CI: 18.61,9.70;
p<0.001), but no longer at T2 (5.15; 95% CI: 10.76,0.47; p = 0.07).
Detailed information on these between-group differences is summa-
rized in Table 2.Fig. 3. CFQ scores over time for the immediate treatment group (ITG) and wait-list
control (WLC) group, based on results of the linear mixed model analyses. CFQ scores
may vary between 0 and 100, with 43 indicating CRCI. In the ITG, there is an esti-
mated mean difference of 18.5 points at T1 (95% CI: 21.73, 15.28; p<0.001) which
continued at T2 (3.85; 95% CI: 7.32, 0.38; p<0.05). For the WLC group, there was
already a significant reduction in sr-CRCI at T1 (4.35; 95% CI: 7.42, 1.28; p<0.01)
which continued at T2 (12.86; 95% CI: 16.11, 9.62; p<0.001).
Legend: blue = immediate treatment group; red = wait-list control group. Error bars
present 95% confidence interval for estimatedmarginalmean (For interpretation of the refer-
ences to color in this figure legend, the reader is referred to theweb version of this article.).3.3. Effect of EFT on secondary PROMs
In line with the primary outcome, the time x group interaction
effect was found to be significant in all secondary PROMs (DT, 38-
item PL, BDI-II and FACIT-fatigue scale) (p<0.005). The results of the
PROMs are illustrated in Fig. 4, and detailed information on the pair-
wise comparisons is summarized in Table 2. The DT, 38-item PL, BDI-
II and FACIT-fatigue scale significantly improved from T0 to T1 in the
ITG group (p<0.001). In the WLC group, the 38-item PL was already
statistically significant improved from T0 to T1 (p<0.01), while the
Table 2
Within-group differences and between-group differences.
Pairwise comparison of the immediate treatment group Pairwise comparison of the wait-list control group Between-group differences
T0 T1 T2 T1 vs T0 T2 vs T0 T2 vs T1 T0 T1 T2 T1 vs T0 T2 vs T0 T2 vs T1 T1 vs T0 T2 vs T0






























p<0.001 p<0.001 p = 0.03 p = 0.006 p<0.001 p<0.001 p<0.001 p = 0.073
















p<0.001 p<0.001 p = 0.760 p = 0.375 p<0.001 p<0.001 p<0.001 p = 0.468
















p<0.001 p<0.001 p = 0.068 p = 0.008 p<0.001 p<0.001 p = 0.001 p = 0.247
















p<0.001 p<0.001 p = 0.589 p = 0.152 p<0.001 p<0.001 p<0.001 p = 0.360




27.51 (2.28) 27.65 (2.32) 33.16 (2.36) 0.14
(2.09,2.38)
5.65 (2.75,8.55) 5.51 (3.17,7.85) 7.01 (3.78,10.25) 3.42
(0.80,7.65)
p<0.001 p<0.001 p = 0.136 p = 0.900 p<0.001 p<0.001 p<0.001 p = 0.112
EORTC QLQ-C30
Summary Score* 68.47 (3.24) 77.56 (3.31) 77.81 (3.38) 9.10 (6.26,11.93) 9.34 (5.52,13.16) 0.24
(2.80,3.29)
70.98 (3.27) 70.31 (3.30) 78.79 (3.35) 0.67
(3.36,2.03)
7.81 (4.21,11.41) 8.47 (5.66,11.29) 9.76 (5.86,13.67) 1.53
(3.72,6.78)
p<0.001 p<0.001 p = 0.875 p = 0.626 p<0.001 p<0.001 p<0.001 p = 0.566
Global Health Status* 51.22 (3.90) 59.79 (4.03) 60.21 (4.13) 8.56 (4.00,13.12) 8.99 (3.18,14.79) 0.42
(4.48,5.33)
55.34 (3.93) 53,78 (3.99) 63.39 (4.08) 1.55
(5.89,2.79)
8.06 (2.57,13.54) 9.61 (5.06,14.16) 10.12 (3.82,16.41) 0.93
(7.06,8.92)
p<0.001 p = 0.003 p = 0.865 p = 0.481 p = 0.004 p<0.001 p = 0.002 p = 0.819
Physical functioning 73.72 (3.97) 80.65 (4.04) 82.64 (4.13) 6.93 (3.45,10.42) 8.92 (4.23,13.62) 1.99
(1.75,5.73)
77.89 (4.00) 79.80 (4.04) 84.58 (4.10) 1.92
(1.39,5.23)
6.70 (2.27,11.12) 4.78 (1.31,8.25) 5.02 (0.21,9.82) 2.23
(4.23,8.68)
p<0.001 p<0.001 p = 0.296 p = 0.255 p = 0.003 p = 0.007 p = 0.041 p = 0.497
Role functioning 45.69 (5.95) 68.19 (6.04) 77.21 (6.18) 22.50 (17.86,27.14) 31.52 (25.10,37.95) 9.02
(3.98,14.06)








p<0.001 p<0.001 p = 0.001 p<0.001 p<0.001 p<0.001 p = 0.065 p = 0.745
















p<0.001 p<0.001 p = 0.313 p = 0.166 p<0.001 p<0.001 p<0.001 p = 0.531
Cognitive functioning* 48.24 (4.80) 69.93 (4.99) 74.21 (5.13) 21.69 (15.30,28.09) 25.98 (18.13,33.83) 4.29
(2.60,11.17)
49.16 (4.83) 51.32 (4.93) 66.10 (5.04) 2.17
(3.92,8.26)




p<0.001 p<0.001 p = 0.221 p = 0.484 p<0.001 p<0.001 p<0.001 p = 0.101
Social functioning 59.17 (5.52) 71.47 (5.72) 70.06 (5.88) 12.30 (5.36,19.24) 10.89 (2.22,19.55) 1.41
(8.88,6.05)
57.69 (5.55) 61.36 (5.66) 68.71 (5.79) 3.67
(2.93,10.28)




p = 0.001 p = 0.014 p = 0.710 p = 0.274 p = 0.009 p = 0.038 p = 0.077 p = 0.983
Fatigue* 60.40 (4.99) 47.28 (5.18) 43.42 (5.32) 13.11 (19.52,6.71) 16.97
(24.93,9.02)








p<0.001 p<0.001 p = 0.271 p = 0.057 p = 0.194 p = 0.001 p<0.001 p = 0.032
















p = 0.129 p = 0.148 p = 0.853 p = 0.855 p = 0.140 p = 0.073 p = 0.230 p = 0.972














p = 0.050 p = 0.195 p = 0.814 p = 0.606 p = 0.159 p = 0.201 p = 0.283 p = 0.980










p = 0.129 p = 0.148 p = 0.853 p = 0.885 p = 0.140 p = 0.073 p = 0.230 p = 0.972




52.26 (7.38) 48.69 (7.54) 35.87 (7.71) 3.57 (12.84,5.70) 16.39 (27.71,5.06) 12.81 (22.55,3.08) 6.79 (20.23,6.65) 8.14 (8.34,
24.62)
p = 0.037 p = 0.176 p = 0.691 p = 0.448 p = 0.005 p = 0.010 p = 0.320 p = 0.332






8.44 (4.34) 11.04 (4.42) 8.94 (4.51) 2.59 (2.38,7.56) 0.50 (5.73,6.73) 2.09 (7.31,3.12) 2.54 (9.74,4.67) 5.14
(14.20,3.93)
p = 0.983 p = 0.167 p = 0.101 p = 0.305 p = 0.875 p = 0.429 p = 0.489 p = 0.266














p = 0.089 p = 0.630 p = 0.319 p = 0.084 p = 0.498 p = 0.013 p = 0.016 p = 0.909
















p = 0.985 p = 0.553 p = 0.482 p = 0.828 p = 0.449 p = 0.272 p = 0.891 p = 0.929








p = 0.005 p = 0.023 p = 0.810 p = 0.197 p = 0.345 p = 0.976 p = 0.251 p = 0.310
EuroQOL EQ-5D-3L 0.63 (0.05) 0.73 (0.05) 0.77 (0.05) 0.09 (0.04,0.14) 0.13 (0.07,0.20) 0.04
(0.01,0.09)
0.65 (0.05) 0.68 (0.05) 0.75 (0.05) 0.03
(0.02,0.08)




p<0.001 p<0.001 p = 0.121 p = 0.196 p = 0.001 p = 0.005 p = 0.074 p = 0.461
Abbreviations: CFQ: Cognitive Failure Questionnaire; PL: Problem List; BDI-II: Beck Depression Inventory II; FACIT: Functional Assessment of Chronic Illness Therapy; EORTC: European Organization for Research and Treatment for Cancer
Quality of Life Questionnaire; EuroQOL: European Quality of Life Scale.
Statistically significant differences are indicated in bold.








Fig. 4. Estimated marginal mean scores over time for secondary PROMs: (A) DT (scores ranging from 0 to 10; high score indicates more distress); (B) 38-item PL (39 items, scores
ranging from 0 to 38; high score indicates more distress); (C) BDI-II (21 items, scores are classified as minimal (013), mild (14-19), moderate (20-28), and severe (29-63)); (D)
FACIT-Fatigue (13 items, scores ranging from 0 to 52; high score indicates less fatigue), separately for both treatment arms in the total study population, based on results of the lin-
ear mixed model analyses.
Results of the linear mixed model analyses indicated that the DT, 38-item PL, BDI-II and FACIT-fatigue scale significantly improved from T0 to T1 in the immediate treatment
group (ITG) (p<0.001). This did not continue at T2 (p>0.05). In the wait-list control (WLC) group, the 38-item PL was already statistically significant improved from T0 to T1
(p<0.01) which continued at T2 (p<0.001). The DT, BDI-II and FACIT-fatigue scale only improved as from T1 in the WLC group (p<0.001).
Legend: blue = immediate treatment group; red = wait-list control group. Error bars present 95% confidence interval for estimated marginal mean.
Abbreviations: PROMs: patient-reported outcome measures; DT: distress thermometer; PL: 38-item problem list (PL); BDI-II: Beck Depression Inventory-II; FACIT-Fatigue:
Functional Assessment of Chronic Illness Therapy-Fatigue Subscale (For interpretation of the references to color in this figure legend, the reader is referred to the web version of
this article.).
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(Table 2).
Similar to the primary outcome CFQ score, the between-group dif-
ference for all secondary endpoints showed a statistically significant
difference at T1 (p<0.001). At T2, the effect of the intervention was
no longer significantly different between both arms (p>0.05; Table 2).
3.4. Effect of EFT on HRQoL
Estimated mean quality of life scores of the EORTC QLQ-C30 scales
are presented in Fig. 5. The scales of EORTC QLQ-C30 were analysed
over time with linear mixed models, as were the primary and othersecondary outcomes. The time x group interaction effect was found
statistically significant for Summary score, GHS, Role functioning,
Emotional functioning, Cognitive functioning and Fatigue and Consti-
pation symptom scale (p<0.05).
Analyses by pairwise comparisons indicated that the EORTC QLQ-
C30 Summary score, the GHS and all functional scales statistically sig-
nificantly improved over time in both arms (p<0.05) (Table 2).
Furthermore, the difference on HRQoL scores of the EORTC QLQ-
C30 between both groups were analysed over time with T0 as refer-
ence time point (Table 2). Summary score, GHS, Physical, Emotional
and Cognitive functioning indicated there was a significant difference
between the ITG and WLC group at T1 vs T0 (p<0.05), and no longer
at T2 vs T0 (p>0.05). The scores on the Fatigue symptom scale on the
Fig. 5. Estimated marginal mean scores over time for HRQoL measures, derived from the EORTC QLQ-C30: (A) Summary Score; (B) Global Health Status; (C) Emotional functioning;
(D) Cognitive functioning; (E) Social functioning; (F) Fatigue, separately for both treatment arms in the total study population, based on results of the linear mixed model analyses.
All of the scales range in score from 0 to 100.
Results of the linear mixed model analyses indicated that the Summary Score, Global Health Status, Emotional functioning, Cognitive functioning, Social functioning and Fatigue
significantly improved from T0 to T1 in the immediate treatment group (ITG) (p<0.001). This did not continue at T2 (p>0.05). For the wait-list control (WLC) group, there was no
significant improvement observed at T1 (p>0.05). Improvement in the WLC for Summary Score (p<0.001), Global Health Status (p<0.001), Emotional functioning (p<0.001) Cogni-
tive functioning (p<0.001), Social functioning (p<0.05) and Fatigue (p = 0.001) was observed at T2.
Legend: blue = immediate treatment group; red = wait-list control group. Error bars present 95% confidence interval for estimated marginal mean.
Abbreviations: HRQoL: health-related quality of life; EORTC QLQ-C30: European Organization for Research and Treatment for Cancer QoL Questionnaire (For interpretation of
the references to color in this figure legend, the reader is referred to the web version of this article.).
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Fig. 6. EuroQoL EQ-5D-3L: Estimated marginal mean scores over time for the immedi-
ate treatment group (ITG) and wait-list control (WLC) group, based on results of the
linear mixed model analyses. These analyses indicated that the EuroQol EQ-5D-3 L
scores significantly improved at all time points when compared to baseline result at T0
in the ITG (p<0.005). In the WLC group, this significant improvement was observed as
from T1 and was maintained until 12 months of follow-up when compared to baseline
result at T0 (p<0.005).
Legend: blue = immediate treatment group; red = wait-list control group. Error
bars present 95% confidence interval for estimated marginal mean.
Abbreviations: EuroQol EQ-5D-3L: instrument including 5 dimensions (mobility,
self-care, usual activities, pain/discomfort, anxiety/depression) with 3 levels of severity
(For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.).
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group at both time points T1 (p<0.001) and T2 (p<0.05) versus refer-
ence time point T0.
Besides the quality of life, the EuroQoL EQ-5D-3 L score or health
state index was measured over the three time periods (T0, T1, T2;
Table 2) and at 6 and 12 months after baseline interview (T0) (Fig. 6).
Six and 12 months after T0, response rate to the follow-up ques-
tionnaires was 77.8% and 75.6% in the ITG group and 84.0% and 68.0%
in the WLC group, respectively. At six months, 60.0% of the ITG group
and 45.2% of the WLC group responded they continued the applica-
tion of EFT. At 12 months follow-up, 55.9% of the ITG group and 35.3%
of the WLC group still applied EFT.
In the ITG group, there was a significant improvement of the
health state index scores at all time points when compared to base-
line result at T0 (p<0.005; data not shown). In the WLC group, this
significant improvement was observed as from T1 and was main-
tained until 12 months of follow-up (p<0.005; data not shown). Pair-
wise comparisons indicated that the strongest improvement in
health state index scores took place after the EFT intervention: T1 vs
T0 for the ITG (p<0.001) and T2 vs T1 for the WLC group (p = 0.005)
(Fig. 6; Table 2).
The estimates of fixed effects show that the EuroQoL EQ-5D-3 L
scores between the ITG and WLC group were not statistically signifi-
cantly different over time, with T0 as reference time point and mea-
sured until follow-up of 12 months (p>0.05; Table 2 for T1 and T2 vs
T0; data not shown for follow-up).
4. Discussion
We aimed to establish EFT as an effective treatment to help cancer
survivors manage sr-CRCI. To the best of our knowledge, this multi-
centre randomised wait-list controlled trial is the first to evaluate the
application of EFT as a tool for improving sr-CRCI. These data showed
that an intervention with EFT reduced subjective cognitive com-
plaints with a difference in proportion of 46.5% between the ITG and
WLC group at T1 (p<0.01), almost twice the assumed difference. Thelinear mixed model analysis established the potential of this inter-
vention by a significant difference in estimated mean CFQ scores at
T1 between both groups (p<0.001). At T2, this between-group differ-
ence was no longer statistically significant as the application of EFT
resulted in a similar reduction in the WLC group, who caught up with
the effect in the ITG.
Perceived cognitive problems are often associated with psycho-
logical factors such as anxiety, depression, fatigue or insomnia [49].
As mentioned recently by Ganz and Van Dyk in their paper on the
impact of chemotherapy and endocrine therapy, patient reported
outcomes on depressive symptoms and fatigue are valuable covari-
ates in their evaluation of changes in CRCI over time because these
common treatment-related symptoms may affect cognitive function
[50]. In this trial, EFT was shown to improve the PROMs such as dis-
tress, depressive symptoms/emotional status and fatigue. These
results are in line with those of previous RCTs where EFT appeared
effective in individuals without cancer for psychological conditions
such as anxiety, depression, phobias and PTSD [27,28,31,34,51].
Cognitive difficulties can have a detrimental effect on a patient’s
HRQoL (autonomy, return to work, social relationships, and self-con-
fidence) in the context of long-term cancer care [49]. When verifying
the clinically relevant outcomes regarding HRQoL after EFT interven-
tion, determined by a difference of 10 points on the EORTC QLQ-
C30 scales, we may conclude that the overall health (EORTC QLQ-C30
Summary Score and GHS), Emotional functioning, Cognitive function-
ing and Fatigue were clinically improved in the ITG compared to the
WLC group at T1. These outcomes support the hypothesis that sub-
jective cognitive complaints impact HRQoL in cancer patients, which
was stated earlier by our research group [9]. The fact that we can
detect significant improvement in HRQoL underlines the importance
of sr-CRCI as opposed to objective cognitive complaints. In this trial,
we decided not to implement a neuropsychological test battery, as
neuropsychological test scores were found insufficiently correlated
with subjectively assessed cognitive symptoms [52,53].
When comparing the EuroQoL EQ-5D-3 L scores between both
groups, we did not observe a difference at any time point. Still, the
health state was improved in both groups when the intervention
with EFT started. Interestingly, 60.0% and 45.2% in the ITG and WLC
group, respectively, responded to continue the application of EFT at
six months follow-up. Moreover, one year after participating in the
EMOTICON trial, 55.9% and 35.3% in the ITG and WLC group, respec-
tively, still applied EFT. We believe this result points out the feasibil-
ity of EFT.
These outcomes support the association of sr-CRCI with psycho-
logical risk factors such as distress, and the efficacy of EFT to improve
quality of life. The results from the EMOTICON trial are in line with a
biopsychosocial model where the occurrence of sr-CRCI does not
only depend on biological or physical factors, but is also affected by
psychological factors and social or environmental factors [54].
There are different other strengths of this study. This is the first
trial to examine the efficacy of EFT to reduce sr-CRCI in a large group
of cancer survivors. EFT is a novel therapy in oncology, but more than
100 studies already acknowledged this technique as a well-estab-
lished evidence-based practice for both physiological and psychologi-
cal symptoms [32,34,55,56]. Second, we believe that the promising
results are very valuable: PROMs are considered the gold standard
for quantifying any possible symptomatic treatment effect in non-
cancer patients. Despite self-report measures may cause (recall) bias,
they are important to understand the patient’s perspective on the
experienced problem. Third, adequate care was taken to ensure
proper conduct of EFT. Furthermore, information sessions were
adjusted to the needs of the patients individually. When necessary,
additional one-on-one practice was foreseen. By only a few contact
moments, patients stated they felt EFT had helped them with their
emotional and physical symptoms. During the planned evaluation
moments, patients could reflect on personal progress. Such
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tional cause such as distress. Therapy by EFT could be a low cost and
low threshold treatment. Research has shown that EFT requires fewer
sessions than CBT and that the effects of an EFT intervention last lon-
ger [57]. Last, the randomised controlled design of the study ensured
a correct distribution of participants over the ITG and WLC group. An
explorative analysis on stratification by age suggested that the cogni-
tive decline experienced by participants was not age-related (data
not shown). Although participants older than 65 years were equally
divided over the ITG and WLC group, the majority is younger than
65 years old. Stratification by cancer type did not occur, which
resulted in a heterogeneous sample. In general, we believe the popu-
lation who benefits the most of these trial results could be female
breast cancer survivors younger than 65 years old.
Due to the COVID-19 pandemic, leading to a government-issued
halt of including new patients in clinical trials in April 2020, we could
only include 121 patients of whom 104 were evaluable at T1. As the
effect observed was much larger than the estimated effect of 25%, the
smaller sample size had no effect on the statistical analysis. Further-
more, by performing linear mixed model analyses, we allowed inclu-
sion of all 121 patients even though some patients had missing
outcomes at T1 and/or T2. Linear mixed model analyses will yield
valid results when these missing outcomes are missing at random.
Analyses were performed on the full analysis set with preservation of
the initial randomization. The small number of males and patients
older than 65 years included in the study may be considered to be a
limitation, as well as the fact that stress response biomarkers were
not measured. Another limitation is the use of the CFQ cut-off score
as both the screener and outcome measure. Also, the use of the CFQ
cut-off as main outcome instead of the continuous score is a limita-
tion. A last limitation is the exploratory nature of the analysis for T2
as there was no pre-defined sample size for this time point.
Future studies will no doubt offer a focused perspective in which
to view the impressive and efficient effects of EFT for use within this
broad array of psychological symptoms. The promising results of
both primary and secondary outcomes, although explorative for T2,
lead us to plan a subsequent trial with the focus on distress and fear
of cancer recurrence. We also plan a post-hoc explorative analysis of
the patient diaries to evaluate participant engagement throughout
the trial. These participant notes may inform us about the problems
EFT was addressed for, which factors lead to continuous application
of EFT measured at follow-up and how to avoid drop-out in future tri-
als because of disbelief of the power of the application of EFT. Fur-
thermore, we will examine if hormonal treatment and the time since
treatment end affect the potential success of EFT as both factors are
known to influence sr-CRCI.
This multicentre randomised wait-list controlled trial demonstrated
that EFT is an effective strategy for patients suffering from sr-CRCI. Fur-
thermore, EFT is associated with multidimensional improvements in
mental well-being and quality of life. These data highlight the importance
of monitoring for sr-CRCI and to implement strategies tomanage sr-CRCI.
This trial highlights EFT as a safe, effective, low cost and low threshold
intervention, easy to implement in clinical practice.Declaration of Competing Interest
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